ARS Pharmaceuticals, Inc.
NASDAQ Global MarketTotal Valuation
ARS Pharmaceuticals, Inc. carries a market capitalization of 412.11M, placing it among publicly traded companies globally. Its enterprise value stands at 749.33M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 412.11M |
| Enterprise Value | 749.33M |
Share Statistics
ARS Pharmaceuticals, Inc. currently has 99.44M shares outstanding.
| Shares Outstanding | 99.44M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 6.79, and the price-to-book ratio stands at 63.66.
| PE Ratio | N/A |
| PS Ratio | 6.79 |
| PB Ratio | 63.66 |
| P/TBV Ratio | -573.85 |
| P/FCF Ratio | -4.05 |
| P/OCF Ratio | -4.04 |
Enterprise Valuation
| EV / Sales | 6.41 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
ARS Pharmaceuticals, Inc. maintains a current ratio of 3.48, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 772.67, indicating elevated leverage, while an interest coverage ratio of -44.39 demonstrates limited ability to service its debt obligations.
| Current Ratio | 3.48 |
| Quick Ratio | 3.13 |
| Debt / Equity | 772.67 |
| Debt / EBITDA | -0.44 |
| Interest Coverage | -44.39 |
Financial Efficiency
| Return on Equity (ROE) | -210.35 |
| Return on Assets (ROA) | -76.53 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 3.28 |
Stock Price Statistics
ARS Pharmaceuticals, Inc.'s stock has declined approximately -56.49895% over the past 52 weeks. The 50-day moving average sits at 5.55, while the 200-day moving average is 8.29.
| Beta (5Y) | N/A |
| 52-Week Price Change | -56.49895% |
| 50-Day Moving Average | 5.55 |
| 200-Day Moving Average | 8.29 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, ARS Pharmaceuticals, Inc. generated 116.93M in revenue and converted that into -215.43M in net income, yielding earnings per share of -2.17. EBITDA reached -218.38M, while operating income came in at -216.27M.
| Revenue | 116.93M |
| Gross Profit | 83.45M |
| Operating Income | -216.27M |
| Pretax Income | -215.51M |
| Net Income | -215.43M |
| EBITDA | -218.38M |
| EBIT | -216.27M |
| Earnings Per Share (EPS) | -2.17 |
Balance Sheet
ARS Pharmaceuticals, Inc. holds 143.85M in cash and equivalents against 96.68M in total debt, resulting in a net debt position of 88.51M. Total book value stands at 12.51M, with working capital of 150.65M providing operational flexibility.
| Cash & Cash Equivalents | 143.85M |
| Total Debt | 96.68M |
| Net Debt | 88.51M |
| Equity (Book Value) | 12.51M |
| Book Value Per Share | 0.13 |
| Working Capital | 150.65M |
Cash Flow
ARS Pharmaceuticals, Inc. produced -196.40M in operating cash flow over the past twelve months. After subtracting -197,000.00 in capital expenditures, free cash flow totaled -196.60M - equivalent to -1.98 per share.
| Operating Cash Flow | -196.40M |
| Capital Expenditures | -197,000.00 |
| Free Cash Flow | -196.60M |
| FCF Per Share | -1.98 |
Margins
ARS Pharmaceuticals, Inc. operates with a gross margin of 71.37, reflecting its pricing power and cost economics. The operating margin of -184.96 and net profit margin of -184.24 provide insight into operational efficiency.
| Gross Margin | 71.37 |
| Operating Margin | -184.96 |
| Pretax Margin | -184.31 |
| Profit Margin | -184.24 |
| EBITDA Margin | -186.77 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -13.12 |
| FCF Yield | -24.71 |
Scores
ARS Pharmaceuticals, Inc. posts an Altman Z-Score of -2.23, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -2.23 |